OTCMKTS:EPRXF Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free EPRXF Stock Alerts C$2.92 -0.08 (-2.67%) (As of 04/24/2024 ET) Add Compare Share Share Today's RangeC$2.80▼C$2.9550-Day RangeC$2.51▼C$5.3752-Week RangeC$2.93▼C$6.78Volume28,641 shsAverage Volume7,410 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Eupraxia Pharmaceuticals alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Eupraxia Pharmaceuticals Stock (OTCMKTS:EPRXF)Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Read More EPRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPRXF Stock News HeadlinesApril 20, 2024 | ca.finance.yahoo.comEupraxia Pharmaceuticals Inc (EPRX-WT.TO)April 18, 2024 | americanbankingnews.comEupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF) Short Interest Down 6.0% in MarchApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 11, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 3, 2024 | finance.yahoo.comEupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024April 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsMarch 29, 2024 | markets.businessinsider.comEQS-News: APONTIS PHARMA expects profitable growth again in 2024April 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 15, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 MillionMarch 12, 2024 | marketwatch.comEupraxia Pharma Shares Drop After Stock Offering PricesMarch 12, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - EPRXMarch 12, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 MillionMarch 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 MillionMarch 1, 2024 | seekingalpha.comProfit Setback For Simcere Pharma In Novel Drugs QuestFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX)February 15, 2024 | msn.comWest Pharmaceutical reports mixed Q4 results; initiates FY24 outlookFebruary 15, 2024 | reuters.comMedical equipment maker West Pharmaceutical forecasts weak annual resultsFebruary 6, 2024 | marketwatch.comVertex Pharmaceuticals 4Q Net, Revenue Beat EstimatesFebruary 5, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisFebruary 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARJanuary 30, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeJanuary 8, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusJanuary 1, 2024 | seekingalpha.comLexicon Pharmaceuticals: Navigating The Competitive HFpEF Landscape (Rating Downgrade)December 16, 2023 | morningstar.comEupraxia Pharmaceuticals Inc Ordinary Shares EPRXDecember 13, 2023 | marketwatch.comEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- UpdateDecember 12, 2023 | ca.finance.yahoo.comStocks in play: Eupraxia Pharmaceuticals Inc.See More Headlines Receive EPRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:EPRXF CUSIPN/A CIKN/A Webwww.eupraxiapharma.com Phone250 590 3968FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price TargetC$18.00 High Stock Price TargetC$18.00 Low Stock Price TargetC$18.00 Potential Upside/Downside+516.4%Consensus RatingStrong Buy Rating Score (0-4)4.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. James A. Helliwell FRCPC (Age 50)M.D., CEO & Director Comp: $463.72kMr. Bruce G. Cousins C.A. (Age 63)CPA, President & CFO Comp: $311.61kDr. Amanda Malone Ph.D. (Age 43)Chief Scientific Officer Comp: $343.63kMr. Paul Anthony Brennan B.Sc.M.Sc., Chief Business OfficerDr. Mark M. Kowalski M.D. (Age 69)Ph.D., Chief Medical Officer Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors EPRXF Stock Analysis - Frequently Asked Questions Should I buy or sell Eupraxia Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eupraxia Pharmaceuticals in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" EPRXF shares. View EPRXF analyst ratings or view top-rated stocks. What is Eupraxia Pharmaceuticals' stock price target for 2024? 1 brokers have issued 1 year price targets for Eupraxia Pharmaceuticals' stock. Their EPRXF share price targets range from C$18.00 to C$18.00. On average, they predict the company's stock price to reach C$18.00 in the next year. This suggests a possible upside of 516.4% from the stock's current price. View analysts price targets for EPRXF or view top-rated stocks among Wall Street analysts. How have EPRXF shares performed in 2024? Eupraxia Pharmaceuticals' stock was trading at C$4.16 at the start of the year. Since then, EPRXF stock has decreased by 29.8% and is now trading at C$2.92. View the best growth stocks for 2024 here. Are investors shorting Eupraxia Pharmaceuticals? Eupraxia Pharmaceuticals saw a decline in short interest in March. As of March 31st, there was short interest totaling 4,700 shares, a decline of 6.0% from the March 15th total of 5,000 shares. Based on an average daily trading volume, of 7,800 shares, the days-to-cover ratio is presently 0.6 days. View Eupraxia Pharmaceuticals' Short Interest. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EPRXF) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
